Nova Eye Medical Limited announces the commencement of a prospective, randomized, single-masked trial across eight surgery centres in the USA to assess the efficacy and safety outcomes of the ab-interno canaloplasty procedure using the company's iTrackTM canaloplasty microcatheter, as compared to the OMNI device (Sight Sciences) in the treatment of mild to moderate glaucoma. Titled MAGIC - Multi-center Ab-interno Glaucoma study Investigating Canaloplasty - the multi- centre trial will be performed over a 12-month period and will enrol 160 patients with mild to moderate, uncontrolled primary open-angle glaucoma (POAG) on 1-4 medications. Patients will be randomized to treatment with the iTrackTM canaloplasty microcatheter and the OMNI® device respectively. The reduction in mean intraocular pressure (IOP) and mean number of anti-glaucoma medications will be assessed, as well as surgical and postoperative complications. The unique mechanism of action of ab-interno canaloplasty, which acts to reduce outflow resistance in all parts of the natural drainage system, further supports its role in the glaucoma treatment armamentarium. Ab-interno canaloplasty is a tissue-sparing, implant-free procedure that acts to re-establish the function of the eye's natural drainage system to effectively reduce IOP and the medication burden, while also preserving the viability of future treatment options. As a result, an increasing number of surgeons are turning to ab-interno canaloplasty to manage their mild-moderate glaucoma patients. In contrast, many other MIGS procedures bypass the natural drainage system or remove tissue. The MAGIC Trial is expected to reinforce the clinical utility of ab-interno canaloplasty in the treatment of mild-moderate glaucoma patients. Details of the trial can be viewed at clinicaltrials.gov, NCT04769453.